Jaguar Health Inc reports results for the quarter ended December 31 - Earnings Summary
01/04/2025 08:38
Jaguar Health Inc JAGX.OQ reported a quarterly adjusted loss of 34 cents per share for the quarter ended December 31. The lone analyst forecast for the quarter was for a loss of $18.50 per share. Revenue rose 50.7% to $3.47 million from a year ago; analysts expected $3.13 million. Jaguar Health Inc's reported EPS for the quarter was a loss of 34 cents. The company reported a quarterly loss of $9.92 million. Jaguar Health Inc shares had held steady so far this quarter and lost 81.1% so far this year. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy" Wall Street's median 12-month price target for Jaguar Health Inc is $150.00 This summary was machine generated from LSEG data April 1 at 07:38 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -18.50 | -0.34 | Beat |
| Sep. 30 2024 | -59.25 | -26.25 | Beat |
| Jun. 30 2024 | -30.00 | -1.01 hundred | Missed |
| Mar. 31 2024 | -45.00 | -1.05 hundred | Missed |